
Opinion|Videos|May 23, 2025
The Future of Chronic Hand Eczema Treatment
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how new treatments for chronic hand eczema (CHE) are emerging, particularly topical delgocitinib cream, a pan-Janus kinase (JAK) inhibitor that shows promise for treating multiple etiologies of the condition without the limitations of traditional topical steroids.
Advertisement
Video content above is prompted by the following:
Future Directions of CHE Treatment
Key Themes:
- Emerging therapies: Topical delgocitinib cream, a pan-JAK inhibitor, shows promise specifically for CHE.
- Other investigational options: Topical ruxolitinib, dupilumab, and tralokinumab have shown efficacy in certain CHE populations.
- Clinical approach: Avoiding treatment delays while pursuing diagnostic workup, with consideration for targeted therapies across multiple etiologies.
Notable Insights:
Dr Chovatiya emphasized that "having a cream that can help patients across etiologies and not delay their actual treatment represents a huge potential win for us in dermatology," suggesting a paradigm shift in CHE management.
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
SUMMIT Substudy Reveals Tirzepatide’s Impact on LV, Atrial Metrics of HFpEF
5

